Is Intuitive Surgical, Inc. (ISRG) A Good Stock To Buy Now?

Key Takeaways

• 70% market share in robotic surgery
• 12,000 da Vinci systems installed worldwide
• Recurring revenue accounts for ~85% of sales
• Procedure volume exceeds three million annually
• Market projected $50B by 2035

Summary

Intuitive Surgical dominates robotic surgery with about 70% market share and roughly 12,000 da Vinci systems installed worldwide. The company generates nearly 85% recurring revenue and performed over three million procedures last year. Its latest da Vinci 5 platform adds advanced computing power and force‑feedback, while the Ion system expands into minimally invasive lung‑cancer diagnostics. Despite a forward P/E near 47 and a recent 10% share decline, analysts view the stock as a long‑term play as the $16 billion market could exceed $50 billion by 2035.

Pulse Analysis

Robotic surgery is moving from niche to mainstream as hospitals seek precision, reduced recovery times, and cost efficiencies. Intuitive Surgical, the clear market leader, benefits from a 70% share and a massive installed base that creates a virtuous cycle of data collection and procedural refinement. The global market, valued at roughly $16 billion in 2026, is projected to more than triple by 2035, driven by expanding adoption in general surgery and untapped international regions. This macro‑trend underpins Intuitive’s growth narrative and fuels investor optimism.

The company’s business model hinges on a razor‑and‑blade approach, with high‑margin instruments and consumables generating about 85% of revenue on a recurring basis. The da Vinci ecosystem, now enhanced by the da Vinci 5’s superior computing and force‑feedback capabilities, deepens surgeon loyalty and raises switching costs. Moreover, the Ion platform diversifies the product suite into diagnostic procedures, opening new revenue streams. A vast patent portfolio and a data moat built from millions of logged surgeries enable continuous AI‑driven improvements, reinforcing the firm’s competitive moat.

Valuation remains a hurdle; a forward P/E of 47 suggests the market has priced in significant growth. However, a recent 10% price dip and modest procedural guidance have created a modest discount to intrinsic expectations. Competition from Medtronic and Johnson & Johnson is intensifying, yet Intuitive’s scale, entrenched training programs, and proven outcomes provide a defensible edge. For investors willing to tolerate premium multiples, the combination of recurring cash flow, expanding addressable market, and durable competitive advantages presents a compelling long‑term investment case.